Basque Country probes rise in psychotropic drug prescriptions

Basque Country investigates why psychotropic drugs are prescribed more often

Figures circulating in the debate over psychotropic drug use in the Basque Country focus on women and vary widely —one in three or one in five, depending on the source— without coming from official cross-referenced data. The paradox lies in the fine print. According to participants, what is being investigated is the increase in prescriptions —what doctors sign off on— not consumption: the study aims to understand why so many are prescribed, not why so many are taken.

This nuance defines the issue. A health phenomenon has become a thermometer for social distress that authorities have decided to tackle via prescriptions, alongside a business —the pill industry— that has grown in parallel. In between, an uncomfortable question remains: if the problem were only about prescriptions, the solution would be simple.

Why investigate prescriptions instead of consumption?

Investigating prescriptions is not the same as investigating consumption, and the difference matters. The debate suggests the system has shifted toward quick fixes: visiting a doctor with a problem ends in pills —whether for hip pain, insomnia, or anxiety— rather than physiotherapy, exercise, or lifestyle changes. Patients seek relief, professionals have limited time, and consultations close with medication.

Others attribute this to demand, not supply: people arrive at the doctor asking for something to calm them down, and the doctor simply provides it.

What the debate takes for granted is the starting point: reliance on tranquilizers and antidepressants is treated as widespread. In this transition, patients cease to be individual cases and become statistics.

Gabapentinoids, fentanyl, and the pill business

The issue extends beyond antidepressants and benzodiazepines. Data from Navarre indicates that 56% of patients use gabapentinoids —drugs indicated for pain— without authorized indications, according to journalistic reports cited in the thread. More than half are using them off-label. Meanwhile, control over fentanyl is considered resolved, shifting the problem to less monitored and easier-to-prescribe drug families.

In parallel, there is the business aspect. The market value of the Danish pharmaceutical company manufacturing a popular weight-loss drug exceeds Denmark's GDP, according to one participant, illustrating where the money flows. The industry does not invent demand but channels, expands, and sustains it, with the bill ultimately landing on the public system.

An economist mentioned years ago noted that governments might eventually facilitate access to certain drugs to pacify restless populations. This idea seemed exaggerated then. Looking at the prescription map, some now read it with less skepticism.

The role-change thesis: assertions versus evidence

Part of the analysis blames the changing role of women. It argues that mass entry into the labor market, exhausting long hours for low wages —cases of twelve-hour shifts for €1,000 are cited— and the dismantling of support networks have multiplied burdens, leading to increased psychotropic use. Some add the empowerment narrative and its pressure to fit molds not everyone is prepared for.

It is important to separate data from interpretation. That consumption is concentrated among women is the impression conveyed by the debate; turning this into a judgment on their character or lifestyle is another matter, and such attributions are made in the thread without proof.

Basque Country and birth rates: an unproven correlation

The Basque Country has Spain's lowest birth rate, as repeated in the thread, and some voices link this to psychotropic consumption as if one explained the other. No one has demonstrated causality. What both phenomena share is context: an aging society, long working hours, scarce care resources, and a thinning family support network.

---

If the problem were truly about prescriptions, adjusting them downward would suffice to close the case. If the failure lies in underlying distress, no prescription reform will touch it, and the system will continue measuring the thermometer instead of addressing the fever. It remains to be seen what the announced investigation concludes, and whether anyone dares to publish the causes missing from the prescription.